Antengene (6996) H2 2025 earnings summary

Executive summary

• Positioned for profitability in 2026, driven by disciplined cost management, continued revenue growth in 2025, and improved operational efficiency.

• Revenue grew 14.5% year-over-year to RMB105.3 million, supported by increased market penetration and commercialization partnerships in Mainland China and APAC.

• Robust clinical pipeline and innovative AnTenGager™ TCE platform underpin multiple revenue streams and global business development deals.

• Major pipeline progress includes expanded approvals and reimbursement for selinexor (XPOVIO®) and strong clinical data for ATG-022 in gastric cancer.

• Commercial products generate revenue in 10 APAC markets, with global expansion and partnerships planned.

Financial highlights

• Cash and bank balances of RMB734 million as of Dec 31, 2025, support pipeline development and strategic initiatives.

• Additional US$80 million in expected licensing revenues (US$60 million upfront, US$20 million near-term milestones).

• R&D costs decreased to RMB169.1 million, reflecting a 23.5% year-over-year reduction and project prioritization.

• Administrative expenses fell 17.7% year-over-year to RMB87.5 million in FY2025.

• Selling and distribution expenses declined 6.2% year-over-year to RMB69.2 million in FY2025.

Outlook and guidance

• Profitability targeted for 2026 and beyond, with multiple revenue streams from new and existing business development deals.

• Focus remains on accelerating development of high-potential clinical assets, especially ATG-022 and ATG-037.

• Global commercialization of first- and best-in-class products expected post-2029, with recurring royalty revenue from partnerships.